The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Thierry Poynard

APHP UPMC Paris Liver Center

Paris

France

[email]@teaser.fr

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • APHP UPMC Paris Liver Center, Paris, France. 2010 - 2012
  • University Pierre and Marie Curie Liver Center, Paris, France. 2010
  • APHP-UPMC-Liver Center, Assistance Publique Hôpitaux de Paris, Université Pierre et Marie Curie, Paris, France. 2010
  • Service d'hépatologie, UPMC Liver Center, hôpital La Pitié Salpêtrière, AP-HP, France. 2009
  • Pitié-Salpêtrière, Université Paris, Paris, France. 2009
  • Service d'Hépato-Gastroentérologie, Groupe Hospitalier Pitié-Salpêtrière, Université Paris VI, CNRS ESA 8067 Paris, France. 1998 - 2009
  • Department of Medicine, University Paris VI, Paris, France. 1999

References

  1. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. Poynard, T., Munteanu, M., Deckmyn, O., Ngo, Y., Drane, F., Castille, J.M., Housset, C., Ratziu, V., Imbert-Bismut, F. J. Hepatol. (2012) [Pubmed]
  2. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. Poynard, T., Lassailly, G., Diaz, E., Clement, K., Caïazzo, R., Tordjman, J., Munteanu, M., Perazzo, H., Demol, B., Callafe, R., Pattou, F., Charlotte, F., Bedossa, P., Mathurin, P., Ratziu, V. PLoS. ONE (2012) [Pubmed]
  3. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. Poynard, T., Munteanu, M., Deckmyn, O., Ngo, Y., Drane, F., Messous, D., Castille, J.M., Housset, C., Ratziu, V., Imbert-Bismut, F. BMC. Gastroenterol (2011) [Pubmed]
  4. FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program. Poynard, T., Munteanu, M., Colombo, M., Bruix, J., Schiff, E., Terg, R., Flamm, S., Moreno-Otero, R., Carrilho, F., Schmidt, W., Berg, T., McGarrity, T., Heathcote, E.J., Gonçales, F., Diago, M., Craxi, A., Silva, M., Boparai, N., Griffel, L., Burroughs, M., Brass, C., Albrecht, J. J. Hepatol. (2011) [Pubmed]
  5. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. Poynard, T., Munteanu, M., Ngo, Y., Castera, L., Halfon, P., Ratziu, V., Imbert-Bismut, F., Thabut, D., Bourliere, M., Cacoub, P., Messous, D., de Ledinghen, V. Gastroenterol. Clin. Biol. (2010) [Pubmed]
  6. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Poynard, T., Ngo, Y., Munteanu, M., Thabut, D., Massard, J., Moussalli, J., Varaud, A., Benhamou, Y., Ratziu, V. Antivir. Ther. (Lond.) (2010) [Pubmed]
  7. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). Poynard, T., Lebray, P., Ingiliz, P., Varaut, A., Varsat, B., Ngo, Y., Norha, P., Munteanu, M., Drane, F., Messous, D., Bismut, F.I., Carrau, J.P., Massard, J., Ratziu, V., Giordanella, J.P. BMC. Gastroenterol (2010) [Pubmed]
  8. Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: an overview of published trials. Poynard, T., Massard, J., Rudler, M., Varaud, A., Lebray, P., Moussalli, J., Munteanu, M., Ngo, Y., Thabut, D., Benhamou, Y., Ratziu, V. Gastroenterol. Clin. Biol. (2009) [Pubmed]
  9. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Poynard, T., Ngo, Y., Marcellin, P., Hadziyannis, S., Ratziu, V., Benhamou, Y. J. Viral Hepat. (2009) [Pubmed]
  10. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Poynard, T., Colombo, M., Bruix, J., Schiff, E., Terg, R., Flamm, S., Moreno-Otero, R., Carrilho, F., Schmidt, W., Berg, T., McGarrity, T., Heathcote, E.J., Gonçales, F., Diago, M., Craxi, A., Silva, M., Bedossa, P., Mukhopadhyay, P., Griffel, L., Burroughs, M., Brass, C., Albrecht, J. Gastroenterology (2009) [Pubmed]
  11. Biomarkers of liver fibrosis. Poynard, T., Morra, R., Ingiliz, P., Imbert-Bismut, F., Thabut, D., Messous, D., Munteanu, M., Massard, J., Benhamou, Y., Ratziu, V. Adv. Clin. Chem (2008) [Pubmed]
  12. Assessment of liver fibrosis: noninvasive means. Poynard, T., Morra, R., Ingiliz, P., Imbert-Bismut, F., Thabut, D., Messous, D., Munteanu, M., Massard, J., Benhamou, Y., Ratziu, V. Saudi. J. Gastroenterol (2008) [Pubmed]
  13. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers. Poynard, T., Ingiliz, P., Elkrief, L., Munteanu, M., Lebray, P., Morra, R., Messous, D., Bismut, F.I., Roulot, D., Benhamou, Y., Thabut, D., Ratziu, V. PLoS. ONE (2008) [Pubmed]
  14. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Poynard, T., Muntenau, M., Morra, R., Ngo, Y., Imbert-Bismut, F., Thabut, D., Messous, D., Massard, J., Lebray, P., Moussalli, J., Benhamou, Y., Ratziu, V. Gastroenterol. Clin. Biol. (2008) [Pubmed]
  15. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Poynard, T., Halfon, P., Castera, L., Munteanu, M., Imbert-Bismut, F., Ratziu, V., Benhamou, Y., Bourlière, M., de Ledinghen, V. Clin. Chem. (2007) [Pubmed]
  16. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Poynard, T., Halfon, P., Castera, L., Charlotte, F., Le Bail, B., Munteanu, M., Messous, D., Ratziu, V., Benhamou, Y., Bourlière, M., De Ledinghen, V. Aliment. Pharmacol. Ther. (2007) [Pubmed]
  17. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?. Poynard, T., Imbert-Bismut, F., Munteanu, M., Ratziu, V. Expert Rev. Mol. Diagn. (2005) [Pubmed]
  18. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Poynard, T., Ratziu, V., Naveau, S., Thabut, D., Charlotte, F., Messous, D., Capron, D., Abella, A., Massard, J., Ngo, Y., Munteanu, M., Mercadier, A., Manns, M., Albrecht, J. Comp. Hepatol (2005) [Pubmed]
  19. Diagnosis and treatment of viral liver fibrosis. Poynard, T., Imbert-Bismut, F., Munteanu, M., Ratziu, V. Saudi. J. Gastroenterol (2005) [Pubmed]
  20. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Poynard, T., Munteanu, M., Imbert-Bismut, F., Charlotte, F., Thabut, D., Le Calvez, S., Messous, D., Thibault, V., Benhamou, Y., Moussalli, J., Ratziu, V. Clin. Chem. (2004) [Pubmed]
  21. Treatment of hepatitis C virus: the first decade. Poynard, T. Semin. Liver Dis. (2004) [Pubmed]
  22. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Poynard, T., Imbert-Bismut, F., Munteanu, M., Messous, D., Myers, R.P., Thabut, D., Ratziu, V., Mercadier, A., Benhamou, Y., Hainque, B. Comp. Hepatol (2004) [Pubmed]
  23. Treatment of cirrhotic patients in the pegylated interferon era. Poynard, T. Dig. Liver. Dis (2004) [Pubmed]
  24. A comparison of fibrosis progression in chronic liver diseases. Poynard, T., Mathurin, P., Lai, C.L., Guyader, D., Poupon, R., Tainturier, M.H., Myers, R.P., Muntenau, M., Ratziu, V., Manns, M., Vogel, A., Capron, F., Chedid, A., Bedossa, P. J. Hepatol. (2003) [Pubmed]
  25. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial. Poynard, T., Marcellin, P., Bissery, A., Myers, R.P., Moussalli, J., Degos, F., Dhumeaux, D., Riachi, G., Bronowicki, J.P., Brissot, P., Buffet, C., Serfaty, L., Naveau, S., Sogni, P., Beaugrand, M., Gayno, S., Larrey, D., Samuel, D., Eugene, C., Pol, S., Bedossa, P., Daurat, V., Chaumet-Riffaud, P. J. Viral Hepat. (2003) [Pubmed]
  26. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Poynard, T., Ratziu, V., McHutchison, J., Manns, M., Goodman, Z., Zeuzem, S., Younossi, Z., Albrecht, J. Hepatology (2003) [Pubmed]
  27. Viral hepatitis C. Poynard, T., Yuen, M.F., Ratziu, V., Lai, C.L. Lancet (2003) [Pubmed]
  28. Interferon for acute hepatitis C. Poynard, T., Regimbeau, C., Myers, R.P., Thevenot, T., Leroy, V., Mathurin, P., Opolon, P., Zarski, J.P. Cochrane. Database. Syst. Rev (2002) [Pubmed]
  29. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. Poynard, T., Imbert-Bismut, F., Ratziu, V., Chevret, S., Jardel, C., Moussalli, J., Messous, D., Degos, F. J. Viral Hepat. (2002) [Pubmed]
  30. Truth survival in clinical research: an evidence-based requiem?. Poynard, T., Munteanu, M., Ratziu, V., Benhamou, Y., Di Martino, V., Taieb, J., Opolon, P. Ann. Intern. Med. (2002) [Pubmed]
  31. Fatigue in patients with chronic hepatitis C. Poynard, T., Cacoub, P., Ratziu, V., Myers, R.P., Dezailles, M.H., Mercadier, A., Ghillani, P., Charlotte, F., Piette, J.C., Moussalli, J. J. Viral Hepat. (2002) [Pubmed]
  32. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Halfon, P., Imbert-Bismut, F., Messous, D., Antoniotti, G., Benchetrit, D., Cart-Lamy, P., Delaporte, G., Doutheau, D., Klump, T., Sala, M., Thibaud, D., Trepo, E., Thabut, D., Myers, R.P., Poynard, T. Comp. Hepatol (2002) [Pubmed]
  33. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Poynard, T., Regimbeau, C., Benhamou, Y. Aliment. Pharmacol. Ther. (2001) [Pubmed]
  34. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. Poynard, T., Ratziu, V., Charlotte, F., Goodman, Z., McHutchison, J., Albrecht, J. J. Hepatol. (2001) [Pubmed]
  35. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Poynard, T., McHutchison, J., Goodman, Z., Ling, M.H., Albrecht, J. Hepatology (2000) [Pubmed]
  36. Appropriateness of liver biopsy. Poynard, T., Ratziu, V., Bedossa, P. Can. J. Gastroenterol. (2000) [Pubmed]
  37. Fibrosis in patients with chronic hepatitis C: detection and significance. Poynard, T., Ratziu, V., Benmanov, Y., Di Martino, V., Bedossa, P., Opolon, P. Semin. Liver Dis. (2000) [Pubmed]
  38. Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival. Multi-centre group. Poynard, T., Naveau, S., Doffoel, M., Boudjema, K., Vanlemmens, C., Mantion, G., Messner, M., Launois, B., Samuel, D., Cherqui, D., Pageaux, G., Bernard, P.H., Calmus, Y., Zarski, J.P., Miguet, J.P., Chaput, J.C. J. Hepatol. (1999) [Pubmed]
  39. Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma. Poynard, T., Moussalli, J., Ratziu, V., Regimbeau, C., Opolon, P. Clin. Liver. Dis (1999) [Pubmed]
  40. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Poynard, T., Marcellin, P., Lee, S.S., Niederau, C., Minuk, G.S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., Albrecht, J. Lancet (1998) [Pubmed]
 
WikiGenes - Universities